AR032070A1 - Uso de cromanos - Google Patents
Uso de cromanosInfo
- Publication number
- AR032070A1 AR032070A1 ARP010106062A ARP010106062A AR032070A1 AR 032070 A1 AR032070 A1 AR 032070A1 AR P010106062 A ARP010106062 A AR P010106062A AR P010106062 A ARP010106062 A AR P010106062A AR 032070 A1 AR032070 A1 AR 032070A1
- Authority
- AR
- Argentina
- Prior art keywords
- chromans
- isopropoxychroman
- benzothiazole
- solvates
- parkinson
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere al uso del 1,1,-dioxido de 2-[4-({[2R)-8-isopropoxicroman-2-il]metil}amino)butil]-1,2-bencisotiazol-3(2H)-ona, de sus sales, hidratos y/o solvatos fisiologicamente aceptables, en especial de su clorhidrato, para la preparacion de un medicamento para la profilaxis y/o tratamiento de la enfermedad de Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10101917A DE10101917A1 (de) | 2001-01-16 | 2001-01-16 | Verwendung von Chromanen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032070A1 true AR032070A1 (es) | 2003-10-22 |
Family
ID=7670832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010106062A AR032070A1 (es) | 2001-01-16 | 2001-12-27 | Uso de cromanos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020177616A1 (es) |
| EP (1) | EP1353670A2 (es) |
| JP (1) | JP2004520342A (es) |
| KR (1) | KR20040025885A (es) |
| CN (1) | CN1529596A (es) |
| AR (1) | AR032070A1 (es) |
| BR (1) | BR0206475A (es) |
| CA (1) | CA2436811A1 (es) |
| DE (1) | DE10101917A1 (es) |
| GT (1) | GT200200002A (es) |
| IL (1) | IL156839A0 (es) |
| MX (1) | MXPA03006333A (es) |
| PE (1) | PE20020841A1 (es) |
| PL (1) | PL362869A1 (es) |
| SV (1) | SV2003000843A (es) |
| UY (1) | UY27123A1 (es) |
| WO (1) | WO2002055078A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2272771T3 (es) * | 2001-09-12 | 2007-05-01 | Merck Patent Gmbh | Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento. |
| EP1856126A2 (en) * | 2005-02-17 | 2007-11-21 | Wyeth a Corporation of the State of Delaware | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19522088A1 (de) * | 1995-06-19 | 1997-01-02 | Bayer Ag | Benzisothiazolyl-substituierte Aminomethylchromane |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| DE19754573A1 (de) * | 1997-12-09 | 1999-06-10 | Bayer Ag | Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma |
-
2001
- 2001-01-16 DE DE10101917A patent/DE10101917A1/de not_active Withdrawn
- 2001-12-27 AR ARP010106062A patent/AR032070A1/es unknown
-
2002
- 2002-01-03 MX MXPA03006333A patent/MXPA03006333A/es unknown
- 2002-01-03 BR BR0206475-8A patent/BR0206475A/pt not_active Application Discontinuation
- 2002-01-03 EP EP02729419A patent/EP1353670A2/de not_active Withdrawn
- 2002-01-03 CA CA002436811A patent/CA2436811A1/en not_active Abandoned
- 2002-01-03 IL IL15683902A patent/IL156839A0/xx unknown
- 2002-01-03 JP JP2002555812A patent/JP2004520342A/ja active Pending
- 2002-01-03 KR KR10-2003-7009409A patent/KR20040025885A/ko not_active Withdrawn
- 2002-01-03 PL PL02362869A patent/PL362869A1/xx not_active Application Discontinuation
- 2002-01-03 WO PCT/EP2002/000007 patent/WO2002055078A2/de not_active Ceased
- 2002-01-03 CN CNA028063554A patent/CN1529596A/zh active Pending
- 2002-01-09 US US10/045,884 patent/US20020177616A1/en not_active Abandoned
- 2002-01-14 UY UY27123A patent/UY27123A1/es not_active Application Discontinuation
- 2002-01-15 PE PE2002000022A patent/PE20020841A1/es not_active Application Discontinuation
- 2002-01-15 SV SV2002000843A patent/SV2003000843A/es not_active Application Discontinuation
- 2002-01-16 GT GT200200002A patent/GT200200002A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040025885A (ko) | 2004-03-26 |
| GT200200002A (es) | 2002-09-02 |
| EP1353670A2 (de) | 2003-10-22 |
| US20020177616A1 (en) | 2002-11-28 |
| WO2002055078A3 (de) | 2003-03-13 |
| WO2002055078A2 (de) | 2002-07-18 |
| JP2004520342A (ja) | 2004-07-08 |
| UY27123A1 (es) | 2002-08-30 |
| CA2436811A1 (en) | 2002-07-18 |
| PE20020841A1 (es) | 2002-10-02 |
| DE10101917A1 (de) | 2002-07-18 |
| PL362869A1 (en) | 2004-11-02 |
| IL156839A0 (en) | 2004-02-08 |
| BR0206475A (pt) | 2003-12-30 |
| MXPA03006333A (es) | 2004-04-20 |
| SV2003000843A (es) | 2003-01-13 |
| CN1529596A (zh) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087241A2 (es) | Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
| BRPI0114870B8 (pt) | uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais | |
| BR0213358A (pt) | Uso de flibanserina | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ATE300306T1 (de) | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| HUP9902808A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| BR0213684A (pt) | Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas | |
| BR0017120A (pt) | Composição farmacêutica | |
| AR032070A1 (es) | Uso de cromanos | |
| AU2003232805A8 (en) | Pharmaceutical active substance combination and the use thereof | |
| SE9902935D0 (sv) | Pharmaceutical compositions | |
| CL2003001692A1 (es) | Uso de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida en la elaboracion de un medicamento para el tratamiento del cancer en un animal de sangre caliente. | |
| HUP0402080A3 (en) | Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease | |
| MY134059A (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
| ATE523498T1 (de) | Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate | |
| TNSN06182A1 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF | |
| DOP2002000326A (es) | Utilizacion de cromanos | |
| SE9902937D0 (sv) | Pharmaceutical compositions | |
| HUP0402654A2 (hu) | 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| BR0208814A (pt) | Uso de derivados de ariletenossulfonamida | |
| BRPI0410704A (pt) | uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |